APO Research
Talk to an analyst

APO RESEARCH · REPORT

Measles, Mumps, and Rubella Virus Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Measles, Mumps, and Rubella Virus Vaccine Market Outlook and Growth Opportunities 2026

22 December 2025199 pages

Choose your research edition.

Industry ResearchMeasles, Mumps, and Rubella Virus Vaccine Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Measles, Mumps, and Rubella Virus Vaccine Industry Growth and Trends Forecast to 203274 pages · $3,450 USDMarket StructureGlobal Measles, Mumps, and Rubella Virus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032174 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Measles, Mumps, and Rubella Virus Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Measles, Mumps, and Rubella Virus Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Measles, Mumps, and Rubella Virus Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Measles, Mumps, and Rubella Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Measles, Mumps, and Rubella Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Measles, Mumps, and Rubella Virus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Measles, Mumps, and Rubella Virus Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Measles, Mumps, and Rubella Virus Vaccine market include Shanghai Institute of Biological, Merck, Beijing Institute of Biological and Minhai Bio, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Measles, Mumps, and Rubella Virus Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Measles, Mumps, and Rubella Virus Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Measles, Mumps, and Rubella Virus Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Measles, Mumps, and Rubella Virus Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Measles, Mumps, and Rubella Virus Vaccine Segment by Company

Shanghai Institute of Biological

Merck

Beijing Institute of Biological

Minhai Bio

Measles, Mumps, and Rubella Virus Vaccine Segment by Type

Child

Adult

Measles, Mumps, and Rubella Virus Vaccine Segment by Application

Public

Private

Measles, Mumps, and Rubella Virus Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Measles, Mumps, and Rubella Virus Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Measles, Mumps, and Rubella Virus Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Measles, Mumps, and Rubella Virus Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Measles, Mumps, and Rubella Virus Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Measles, Mumps, and Rubella Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Measles, Mumps, and Rubella Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Measles, Mumps, and Rubella Virus Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Measles, Mumps, and Rubella Virus Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Measles, Mumps, and Rubella Virus Vaccine industry.

Chapter 3: Detailed analysis of Measles, Mumps, and Rubella Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Measles, Mumps, and Rubella Virus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Measles, Mumps, and Rubella Virus Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Measles, Mumps, and Rubella Virus Vaccine Industry Trends Table 2. Measles, Mumps, and Rubella Virus Vaccine Industry Drivers Table 3. Measles, Mumps, and Rubella Virus Vaccine Industry Opportunities and Challenges Table 4. Measles, Mumps, and Rubella Virus Vaccine Industry Restraints Table 5. Global Measles, Mumps, and Rubella Virus Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Measles, Mumps, and Rubella Virus Vaccine Revenue Share by Company (2021-2026) Table 7. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Measles, Mumps, and Rubella Virus Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Measles, Mumps, and Rubella Virus Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Measles, Mumps, and Rubella Virus Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Measles, Mumps, and Rubella Virus Vaccine Company, Product Type & Application Table 13. Global Measles, Mumps, and Rubella Virus Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Measles, Mumps, and Rubella Virus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Child Table 18. Significant Companies of Adult Table 19. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Public Table 30. Significant Companies of Private Table 31. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Application (2021-2026) & (k units) Table 33. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Application (2027-2032) & (k units) Table 34. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Measles, Mumps, and Rubella Virus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Measles, Mumps, and Rubella Virus Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global Measles, Mumps, and Rubella Virus Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Measles, Mumps, and Rubella Virus Vaccine Sales by Region (2027-2032) & (k units) Table 45. Global Measles, Mumps, and Rubella Virus Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Measles, Mumps, and Rubella Virus Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Measles, Mumps, and Rubella Virus Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Measles, Mumps, and Rubella Virus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Measles, Mumps, and Rubella Virus Vaccine Sales by Country (2021-2026) & (k units) Table 56. Global Measles, Mumps, and Rubella Virus Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Measles, Mumps, and Rubella Virus Vaccine Sales by Country (2027-2032) & (k units) Table 58. Global Measles, Mumps, and Rubella Virus Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Shanghai Institute of Biological Company Information Table 64. Shanghai Institute of Biological Business Overview Table 65. Shanghai Institute of Biological Measles, Mumps, and Rubella Virus Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Shanghai Institute of Biological Measles, Mumps, and Rubella Virus Vaccine Product Portfolio Table 67. Shanghai Institute of Biological Recent Development Table 68. Merck Company Information Table 69. Merck Business Overview Table 70. Merck Measles, Mumps, and Rubella Virus Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. Merck Measles, Mumps, and Rubella Virus Vaccine Product Portfolio Table 72. Merck Recent Development Table 73. Beijing Institute of Biological Company Information Table 74. Beijing Institute of Biological Business Overview Table 75. Beijing Institute of Biological Measles, Mumps, and Rubella Virus Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Beijing Institute of Biological Measles, Mumps, and Rubella Virus Vaccine Product Portfolio Table 77. Beijing Institute of Biological Recent Development Table 78. Minhai Bio Company Information Table 79. Minhai Bio Business Overview Table 80. Minhai Bio Measles, Mumps, and Rubella Virus Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. Minhai Bio Measles, Mumps, and Rubella Virus Vaccine Product Portfolio Table 82. Minhai Bio Recent Development Table 83. Key Raw Materials Table 84. Raw Materials Key Suppliers Table 85. Measles, Mumps, and Rubella Virus Vaccine Distributors List Table 86. Measles, Mumps, and Rubella Virus Vaccine Customers List Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Measles, Mumps, and Rubella Virus Vaccine Product Image Figure 2. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Measles, Mumps, and Rubella Virus Vaccine Sales (2021-2032) & (k units) Figure 5. Global Measles, Mumps, and Rubella Virus Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Measles, Mumps, and Rubella Virus Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Child Image Figure 10. Adult Image Figure 11. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type (2021-2032) Figure 17. Public Image Figure 18. Private Image Figure 19. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Measles, Mumps, and Rubella Virus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Measles, Mumps, and Rubella Virus Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Measles, Mumps, and Rubella Virus Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Measles, Mumps, and Rubella Virus Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Child
  • Adult
Applications
  • Public
  • Private
Companies covered
  • Shanghai Institute of Biological
  • Merck
  • Beijing Institute of Biological
  • Minhai Bio

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Measles, Mumps, and Rubella Virus Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Measles, Mumps, and Rubella Virus Vaccine Market Dynamics
  1. 2.1 Measles, Mumps, and Rubella Virus Vaccine Industry Trends
  2. 2.2 Measles, Mumps, and Rubella Virus Vaccine Industry Drivers
  3. 2.3 Measles, Mumps, and Rubella Virus Vaccine Industry Opportunities and Challenges
  4. 2.4 Measles, Mumps, and Rubella Virus Vaccine Industry Restraints
3 Measles, Mumps, and Rubella Virus Vaccine Market by Company
  1. 3.1 Global Measles, Mumps, and Rubella Virus Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Measles, Mumps, and Rubella Virus Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Measles, Mumps, and Rubella Virus Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Measles, Mumps, and Rubella Virus Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Measles, Mumps, and Rubella Virus Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Measles, Mumps, and Rubella Virus Vaccine Company Product Type and Application
  8. 3.8 Global Measles, Mumps, and Rubella Virus Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Measles, Mumps, and Rubella Virus Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Measles, Mumps, and Rubella Virus Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Measles, Mumps, and Rubella Virus Vaccine Market by Type
  1. 4.1 Measles, Mumps, and Rubella Virus Vaccine Type Introduction
  2. 4.1.1 Child
  3. 4.1.2 Adult
  4. 4.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Type
  5. 4.2.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Type
  9. 4.3.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type (2021-2032)
5 Measles, Mumps, and Rubella Virus Vaccine Market by Application
  1. 5.1 Measles, Mumps, and Rubella Virus Vaccine Application Introduction
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Application
  5. 5.2.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Measles, Mumps, and Rubella Virus Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Application
  9. 5.3.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application (2021-2032)
6 Measles, Mumps, and Rubella Virus Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Measles, Mumps, and Rubella Virus Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Measles, Mumps, and Rubella Virus Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Country, 2025 VS 2032
7 Measles, Mumps, and Rubella Virus Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Measles, Mumps, and Rubella Virus Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Measles, Mumps, and Rubella Virus Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Measles, Mumps, and Rubella Virus Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Measles, Mumps, and Rubella Virus Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Shanghai Institute of Biological
  2. 8.1.1 Shanghai Institute of Biological Company Information
  3. 8.1.2 Shanghai Institute of Biological Business Overview
  4. 8.1.3 Shanghai Institute of Biological Measles, Mumps, and Rubella Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Shanghai Institute of Biological Measles, Mumps, and Rubella Virus Vaccine Product Portfolio
  6. 8.1.5 Shanghai Institute of Biological Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Measles, Mumps, and Rubella Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Measles, Mumps, and Rubella Virus Vaccine Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Beijing Institute of Biological
  14. 8.3.1 Beijing Institute of Biological Company Information
  15. 8.3.2 Beijing Institute of Biological Business Overview
  16. 8.3.3 Beijing Institute of Biological Measles, Mumps, and Rubella Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Beijing Institute of Biological Measles, Mumps, and Rubella Virus Vaccine Product Portfolio
  18. 8.3.5 Beijing Institute of Biological Recent Developments
  19. 8.4 Minhai Bio
  20. 8.4.1 Minhai Bio Company Information
  21. 8.4.2 Minhai Bio Business Overview
  22. 8.4.3 Minhai Bio Measles, Mumps, and Rubella Virus Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Minhai Bio Measles, Mumps, and Rubella Virus Vaccine Product Portfolio
  24. 8.4.5 Minhai Bio Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Measles, Mumps, and Rubella Virus Vaccine Value Chain Analysis
  2. 9.1.1 Measles, Mumps, and Rubella Virus Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Measles, Mumps, and Rubella Virus Vaccine Sales Mode & Process
  6. 9.2 Measles, Mumps, and Rubella Virus Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Measles, Mumps, and Rubella Virus Vaccine Distributors
  9. 9.2.3 Measles, Mumps, and Rubella Virus Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst